Screener / SEC EDGAR /CIK 0001014739 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

Option Care Health, Inc. OPCH

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 24, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-20.1%

“The change in cash provided by operating activities during the year ended December 31, 2025 was primarily due to increases in inventories due to strategic purchases and a focus on maximizing the impact from volume based rebates and prompt pay purchase discounts.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+13.0%

“The increase in net revenue during the year ended December 31, 2025 was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had mid-teens growth relative to the prior year while chronic revenue grew in the low double-digits.”

Read it in the 10-K

Gross margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

20.3% to 19.3% (-1.0 pts)

“The increase in cost of revenue was primarily driven by the growth in revenue and therapy mix.”

Read it in the 10-K

“The decrease in gross profit margin was primarily due to mix, including certain higher cost therapies included within chronic growth (including rare and orphan therapies) as well as biosimilar adoption, partially offset by certain mitigation efforts executed in the first quarter of 2025.”

Read it in the 10-K

Operating margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

6.4% to 6.0% (-0.5 pts)

“Selling, general and administrative expenses have declined as a percentage of revenue to 12.1% for the year ended December 31, 2025 compared to 12.6% for the year ended December 31, 2024, due to the Company’s focus on leveraging existing infrastructure to control spending.”

Read it in the 10-K

Net income

Change, FY to Dec 31, 2025 vs Dec 31, 2024

-2.0%

The MD&A has no sentence that names a cause for this change.

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +13.0%

    “The increase in net revenue during the year ended December 31, 2025 was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had mid-teens growth relative to the prior year while chronic revenue grew in the low double-digits.”

    Read it in the FY 2025 10-K
  • FY 2024 +16.3%

    “The increase in net revenue during the year ended December 31, 2024 was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had high single digits growth relative to the prior year while chronic revenue grew in the high teens.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 -1.0 pts

    “The increase in cost of revenue was primarily driven by the growth in revenue and therapy mix.”

    Read it in the FY 2025 10-K

    “The decrease in gross profit margin was primarily due to mix, including certain higher cost therapies included within chronic growth (including rare and orphan therapies) as well as biosimilar adoption, partially offset by certain mitigation efforts executed in the first quarter of 2025.”

    Read it in the FY 2025 10-K
  • FY 2024 -2.6 pts

    “The increase in cost of revenue was primarily driven by the growth in revenue, therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year.”

    Read it in the FY 2024 10-K

    “The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of certain temporary favorable procurement dynamics in the prior year that did not continue into 2024.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 -0.5 pts

    “Selling, general and administrative expenses have declined as a percentage of revenue to 12.1% for the year ended December 31, 2025 compared to 12.6% for the year ended December 31, 2024, due to the Company’s focus on leveraging existing infrastructure to control spending.”

    Read it in the FY 2025 10-K
  • FY 2024 -0.9 pts

    “The increase in selling, general and administrative expenses during the year ended December 31, 2024 was primarily due to an increase in salaries, benefits, and general costs to support the business; however, these expenses have declined as a percentage of revenue to 12.6% for the year ended December 31, 2024 compared to 14.1% for the year ended December 31, 2023, due to the Company’s focus on leveraging existing infrastructure to control spending.”

    Read it in the FY 2024 10-K

Net income

0 of 2 years explained
  • FY 2025 -2.0%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 -20.7%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

2 of 2 years explained
  • FY 2025 -20.1%

    “The change in cash provided by operating activities during the year ended December 31, 2025 was primarily due to increases in inventories due to strategic purchases and a focus on maximizing the impact from volume based rebates and prompt pay purchase discounts.”

    Read it in the FY 2025 10-K
  • FY 2024 -12.9%

    “The decrease in cash provided by operating activities during the year ended December 31, 2024 was primarily due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023, changes in accounts receivable and accrued compensation and employee benefits.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OPCH/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.